ROBERT CHESS - 16 Sep 2022 Form 4 Insider Report for NEKTAR THERAPEUTICS (NKTR)

Role
Director
Signature
Mark A. Wilson, Attorney-in-Fact
Issuer symbol
NKTR
Transactions as of
16 Sep 2022
Net transactions value
$0
Form type
4
Filing time
20 Sep 2022, 20:45:05 UTC
Previous filing
10 Feb 2022
Next filing
26 Sep 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction NKTR Common Stock Award $0 +10,200 +4.6% $0.000000 233,279 16 Sep 2022 Direct F1, F2
holding NKTR Common Stock 2,100 16 Sep 2022 by daughter F3
holding NKTR Common Stock 2,100 16 Sep 2022 by son F3
holding NKTR Common Stock 2,100 16 Sep 2022 by daughter F3
holding NKTR Common Stock 28,794 16 Sep 2022 by Robert Chess Grantor Retained Annuity Trust
holding NKTR Common Stock 28,000 16 Sep 2022 by Stacey Chess Grantor Retained Annuity Trust

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction NKTR Stock Option Award $0 +20,400 $0.000000 20,400 16 Sep 2022 Common Stock 20,400 $3.47 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Common stock was acquired pursuant to a grant of restricted stock units ("RSUs"). Each RSU awarded represents a contingent right to receive, upon vesting of the unit, one share of the Issuer's common stock.
F2 This RSU award vests in full, one year following September 16, 2022.
F3 The reporting person disclaims beneficial ownership of these shares, and this report shall not be deemed an admission that the reporting person is the beneficial owner of these shares for purposes of Section 16 or for any other purpose.
F4 This stock option vests in equal monthly installments over the one-year period beginning on September 16, 2022.